A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Ray-Coquard, Isabelle
  • Haluska, Paul
  • O'Reilly, Seamus
  • Cottu, Paul H
  • Elit, Laurie
  • Provencher, Diane M
  • Beckmann, Matthias W
  • Bosserman, Linda D
  • Jacod, Sylvie
  • Houe, Vincent
  • Loberg, Robert D
  • Glaspy, John A
  • Karlan, Beth
  • Slamon, Dennis J
  • Konecny, Gottfried E

publication date

  • May 20, 2013